Quick Answer
Foghorn Therapeutics Inc. reported Total Revenue of $30.91 million for fiscal year 2025.
Foghorn Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $30.91M +36.8% |
$22.60M -33.8% |
$34.16M +77.6% |
$19.23M +1357.8% |
$1.32M +206.7% |
$430.0K |
| Revenue (ASC 606) | $30.91M +36.8% |
$22.60M -33.8% |
$34.16M +77.6% |
$19.23M +1357.8% |
$1.32M +206.7% |
$430.0K |
| Net Income | -$74.28M +14.2% |
-$86.62M +12.0% |
-$98.43M +9.6% |
-$108.88M -7.5% |
-$101.32M -47.3% |
-$68.80M -34.6% |
| Diluted EPS | -$1.18 +25.3% |
-$1.58 +32.5% |
-$2.34 +10.7% |
-$2.62 +4.0% |
-$2.73 +56.2% |
-$6.23 |
| Total Assets | $198.10M -30.2% |
$283.98M -0.7% |
$285.92M -29.4% |
$404.88M -22.1% |
$519.77M +103.4% |
$255.59M +1044.0% |
| Cash and Equivalents | $80.88M +45.8% |
$55.45M -31.0% |
$80.34M +53.9% |
$52.21M -48.4% |
$101.14M +9.0% |
$92.80M +519.4% |
| Long-Term Debt | — | — | — | — | $0.00 -100.0% |
$19.65M +79.3% |
| Stockholders Equity | -$108.50M -138.3% |
-$45.53M +41.0% |
-$77.19M -69019.6% |
$112.0K -99.9% |
$96.87M -33.7% |
$146.19M +266.1% |
| R&D Expense | $85.47M -9.6% |
$94.53M -13.8% |
$109.69M +3.9% |
$105.62M +31.5% |
$80.33M +39.2% |
$57.72M +30.1% |
| Operating Income | -$86.39M +15.9% |
-$102.68M +4.8% |
-$107.91M +7.9% |
-$117.14M -16.3% |
-$100.73M -47.0% |
-$68.53M -34.2% |
| Shares Outstanding | 56.66M +1.9% |
55.59M +31.5% |
42.28M +1.1% |
41.80M +1.2% |
41.30M +12.3% |
36.79M +655.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $8.15M | +4.4% | +7.9% |
| Revenue (ASC 606) | September 30, 2025 | $8.15M | +4.4% | +7.9% |
| Net Income | September 30, 2025 | -$15.85M | +17.1% | +11.6% |
| Diluted EPS | September 30, 2025 | -$0.25 | +19.4% | +10.7% |
| Total Assets | September 30, 2025 | $204.96M | -33.5% | -9.4% |
| Cash and Equivalents | September 30, 2025 | $89.33M | +54.9% | +23.1% |
| Long-Term Debt | September 30, 2021 | $19.91M | +126.3% | +0.4% |
| Stockholders Equity | September 30, 2025 | -$89.66M | -217.0% | -17.0% |
| R&D Expense | September 30, 2025 | $20.00M | -19.0% | -8.2% |
| Operating Income | September 30, 2025 | -$18.50M | +22.4% | +12.3% |
| Shares Outstanding | September 30, 2025 | 56.54M | +1.7% | +1.3% |
- Foghorn Therapeutics Inc. reported Total Revenue of $30.91 million for fiscal year 2025.
- Foghorn Therapeutics Inc. showed an increase of +36.8% in Total Revenue compared to the prior fiscal year.
- Foghorn Therapeutics Inc. reported Revenue (ASC 606) of $30.91 million for fiscal year 2025.
- Foghorn Therapeutics Inc. showed an increase of +36.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Foghorn Therapeutics Inc. reported Net Income of -$74.28 million for fiscal year 2025.
- Foghorn Therapeutics Inc. showed an increase of +14.2% in Net Income compared to the prior fiscal year.
- Foghorn Therapeutics Inc. reported Diluted EPS of $1.18 per share (loss) for fiscal year 2025.
- Foghorn Therapeutics Inc. showed an increase of +25.3% in Diluted EPS compared to the prior fiscal year.
- Foghorn Therapeutics Inc. reported Total Assets of $198.10 million for fiscal year 2025.
- Foghorn Therapeutics Inc. showed a decrease of -30.2% in Total Assets compared to the prior fiscal year.
- Foghorn Therapeutics Inc. reported Cash and Equivalents of $80.88 million for fiscal year 2025.
- Foghorn Therapeutics Inc. showed an increase of +45.8% in Cash and Equivalents compared to the prior fiscal year.
- Foghorn Therapeutics Inc. reported Long-Term Debt of $0.00 for fiscal year 2021.
- Foghorn Therapeutics Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Foghorn Therapeutics Inc. reported Stockholders Equity of -$108.50 million for fiscal year 2025.
- Foghorn Therapeutics Inc. showed a decrease of -138.3% in Stockholders Equity compared to the prior fiscal year.
- Foghorn Therapeutics Inc. reported R&D Expense of $85.47 million for fiscal year 2025.
- Foghorn Therapeutics Inc. showed a decrease of -9.6% in R&D Expense compared to the prior fiscal year.
- Foghorn Therapeutics Inc. reported Operating Income of -$86.39 million for fiscal year 2025.
- Foghorn Therapeutics Inc. showed an increase of +15.9% in Operating Income compared to the prior fiscal year.
- Foghorn Therapeutics Inc. reported Shares Outstanding of 56.66 million shares for fiscal year 2025.
- Foghorn Therapeutics Inc. showed an increase of +1.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: